UnknownPhase 3

A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Evaluate the Clinical Efficacy and Safety of Yogliptin Tablets

China450 participantsStarted 2022-01-01

Plain-language summary

The purpose of this study is to assess the efficacy of Yogliptin (as monotherapy) compared with placebo after 24 weeks, and the safety (up to 52 weeks) of Yogliptin in Chinese patients with Type 2 diabetes who are insufficient glycaemic control with diet and exercise.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓.fasting blood glucose(FPG): Screening period: FPG≤15.0mmol/L (tested by the research center), when randomly enrolled: FPG≤15.0mmol/L (central laboratory test) Measurement);

What they're measuring

HbA1c change from baseline at week 24

Timeframe: Baseline and week 24

Trial details

NCT IDNCT05318326

SponsorChengdu Easton Biopharmaceuticals Co,Ltd

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2024-12-31

Contact for this trial

yunju Yi

+8613518115493 yiyunju@eastonpharma.cn

View on ClinicalTrials.gov More Type 2 Diabetes trials